REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in the Angiogenesis, Exudation, and Degeneration 2021 conference on February 12-13, 2021. Two oral presentations will showcase advancements in gene therapy for eye diseases:

• Subretinal Gene Therapy for Exudative AMD by Allen C. Ho, M.D. on February 13 at 9:15 a.m. ET
• Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy by Peter A. Campochiaro, M.D. on February 13 at 9:45 a.m. ET

These presentations highlight the company's innovative approaches using its NAV® Technology Platform.

Positive

• Participation in a significant conference indicates ongoing research and development.
• Presentations by notable experts may enhance company credibility and visibility.

Negative

• None.

ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021.

The presentations will be as follows:

Presentation Title: Subretinal Gene Therapy for Exudative AMD
Presenter: Allen C. Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina
Date/Time: Saturday, February 13, 2021, 9:15 a.m. ET

Presentation Title: Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Presenter: Peter A. Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
Date/Time: Saturday, February 13, 2021, 9:45 a.m. ET

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Trademarks referenced herein are registered trademarks of REGENXBIO.

Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2021-conference-301222819.html

SOURCE REGENXBIO Inc.

FAQ

What is REGENXBIO presenting at the Angiogenesis, Exudation, and Degeneration 2021 conference?

REGENXBIO is presenting two oral presentations on gene therapy for eye diseases on February 13, 2021.

Who are the presenters for REGENXBIO at the conference?

The presenters are Allen C. Ho, M.D. and Peter A. Campochiaro, M.D.

When will REGENXBIO's presentations take place?

The presentations will take place on February 13, 2021, at 9:15 a.m. ET and 9:45 a.m. ET.

What is the significance of REGENXBIO's NAV® Technology Platform?

The NAV® Technology Platform is crucial for developing gene therapies and includes exclusive rights to numerous novel AAV vectors.